Erenumab-aooe for Temporomandibular Disorders Management: TMD Cgrp Antibody RElief (TMD CARE)

NCT05162027 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

5

Enrollment

OTHER

Sponsor class

Stopped Low enrollment rate

Conditions

Temporomandibular Disorders

Interventions

DRUG: Erenumab-Aooe 70 MG in 1 mL Prefilled Syringe
DRUG: Placebo

Sponsor

University of Maryland, Baltimore

Collaborators

[object Object]